This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q1 results later this week.
Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges
by Sanghamitra Saha
Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
by Kinjel Shah
JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.
Here's How You Should Play JNJ Stock After Q1 Earnings Beat
by Kinjel Shah
Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Buy These Defensive Stocks After Beating Earnings Expectations?: ACI, JNJ
by Shaun Pruitt
Johnson & Johnson (JNJ) and Albertsons Companies' (ACI) stock have provided a pleasant hedge against market volatility and were able to exceed their quarterly expectations on Wednesday.
ETFs in Focus Post JNJ's Q1 Earnings Beat, Dividend Hike
by Sweta Killa
Johnson & Johnson reports strong first-quarter 2025 results, raises revenue guidance and boosts its quarterly dividends.
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal
by Zacks Equity Research
J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.
Import Prices Turn Negative for First Time Since September
by Zacks Equity Research
Import Prices Turn Negative for First Time Since September
Import Prices, Empire State Come In Mild; Q1 Earnings Beats Abound
by Mark Vickery
Pre-markets are down somewhat, following yesterday's +3/4-percent gain on the Dow and the S&P 500, +2/3-percent gain for the Nasdaq.
Compared to Estimates, Johnson & Johnson (JNJ) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson (JNJ) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 7.78% and 1.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Can ISRG Stock Revive its Growth Momentum After the Sudden Slide?
by Indrajit Bandyopadhyay
Intuitive Surgical has maintained an uptrend since late 2022 with price correcting to 200-DMA a few times and again continuing the uptrend. Will it repeat?
JPMorgan, Wells Fargo, Morgan Stanley, Netflix, UnitedHealthcare, Johnson & Johnson and CSX Corp are part of Zacks Earnings Preview
by Zacks Equity Research
JPMorgan, Wells Fargo, Morgan Stanley, Netflix, UnitedHealthcare, Johnson & Johnson and CSX Corp have been highlighted in this Earnings Preview article.
Novartis (NVS) Surges 4.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Novartis (NVS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings
by Kinjel Shah
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. We do not expect any improvement in MedTech sales.
Is First Trust Dow 30 Equal Weight ETF (EDOW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EDOW
Seeking Clues to Johnson & Johnson (JNJ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTCS
Johnson & Johnson (JNJ) Stock Moves -0.52%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $149.83, marking a -0.52% move from the previous day.
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH